JP2010519206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519206A5 JP2010519206A5 JP2009549637A JP2009549637A JP2010519206A5 JP 2010519206 A5 JP2010519206 A5 JP 2010519206A5 JP 2009549637 A JP2009549637 A JP 2009549637A JP 2009549637 A JP2009549637 A JP 2009549637A JP 2010519206 A5 JP2010519206 A5 JP 2010519206A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- optionally substituted
- optionally
- nr6r7
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 132
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- -1 pyrrolo [2,3] pyrimidyl Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 4
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 102000004310 Ion Channels Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 2
- 230000005931 immune cell recruitment Effects 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- NUIDMUUKGHMEKR-UHFFFAOYSA-N 2,6-difluoro-n-(5-phenyl-8,9-dihydro-7h-benzo[7]annulen-2-yl)benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C2C(C=3C=CC=CC=3)=CCCCC2=C1 NUIDMUUKGHMEKR-UHFFFAOYSA-N 0.000 claims 1
- UOXYJSHABNCKNS-UHFFFAOYSA-N 2,6-difluoro-n-(6-methyl-5-phenyl-8,9-dihydro-7h-benzo[7]annulen-2-yl)benzamide Chemical compound C12=CC=C(NC(=O)C=3C(=CC=CC=3F)F)C=C2CCCC(C)=C1C1=CC=CC=C1 UOXYJSHABNCKNS-UHFFFAOYSA-N 0.000 claims 1
- QAMPHGFSHGCJIX-UHFFFAOYSA-N 2,6-difluoro-n-[5-(1-hydroxypropan-2-ylidene)-7,8-dihydro-6h-naphthalen-2-yl]benzamide Chemical compound C=1C=C2C(=C(CO)C)CCCC2=CC=1NC(=O)C1=C(F)C=CC=C1F QAMPHGFSHGCJIX-UHFFFAOYSA-N 0.000 claims 1
- HWXCHHLTRJYJAQ-UHFFFAOYSA-N 2,6-difluoro-n-[5-(1-morpholin-4-yl-1-oxopropan-2-ylidene)-7,8-dihydro-6h-naphthalen-2-yl]benzamide Chemical compound C1CCC2=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=C2C1=C(C)C(=O)N1CCOCC1 HWXCHHLTRJYJAQ-UHFFFAOYSA-N 0.000 claims 1
- ZKXLUFVYPVWURV-UHFFFAOYSA-N 2-[6-[(2,5-difluorobenzoyl)amino]-3,4-dihydro-2h-naphthalen-1-ylidene]propyl acetate Chemical compound C=1C=C2C(=C(C)COC(=O)C)CCCC2=CC=1NC(=O)C1=CC(F)=CC=C1F ZKXLUFVYPVWURV-UHFFFAOYSA-N 0.000 claims 1
- IIOKZLFWNFGSCR-UHFFFAOYSA-N 2-[6-[(2,6-difluorobenzoyl)amino]-3,4-dihydro-2h-naphthalen-1-ylidene]propanoic acid Chemical compound C=1C=C2C(=C(C(O)=O)C)CCCC2=CC=1NC(=O)C1=C(F)C=CC=C1F IIOKZLFWNFGSCR-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000024035 chronic otitis media Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- XNMOKWWWKFDIJO-UHFFFAOYSA-N methyl 2-[6-[(2,6-difluorobenzoyl)amino]-3,4-dihydro-2h-naphthalen-1-ylidene]propanoate Chemical compound C=1C=C2C(=C(C)C(=O)OC)CCCC2=CC=1NC(=O)C1=C(F)C=CC=C1F XNMOKWWWKFDIJO-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- XEPFNBTVFLNZNY-UHFFFAOYSA-N n-[5-(4-acetamidophenyl)-8,9-dihydro-7h-benzo[7]annulen-2-yl]-2,6-difluorobenzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=CCCCC2=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=C12 XEPFNBTVFLNZNY-UHFFFAOYSA-N 0.000 claims 1
- PUQPKMHRRQJQLH-UHFFFAOYSA-N n-[5-(4-aminophenyl)-8,9-dihydro-7h-benzo[7]annulen-2-yl]-2,6-difluorobenzamide Chemical compound C1=CC(N)=CC=C1C1=CCCCC2=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=C12 PUQPKMHRRQJQLH-UHFFFAOYSA-N 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90194907P | 2007-02-16 | 2007-02-16 | |
| PCT/US2008/002077 WO2008103310A1 (en) | 2007-02-16 | 2008-02-15 | Substituted fused-ring compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010519206A JP2010519206A (ja) | 2010-06-03 |
| JP2010519206A5 true JP2010519206A5 (enExample) | 2011-03-31 |
Family
ID=39710369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549637A Pending JP2010519206A (ja) | 2007-02-16 | 2008-02-15 | 炎症及び免疫関連使用のための置換縮合環化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8809396B2 (enExample) |
| EP (1) | EP2129219A4 (enExample) |
| JP (1) | JP2010519206A (enExample) |
| AU (1) | AU2008219115A1 (enExample) |
| CA (1) | CA2678615A1 (enExample) |
| TW (1) | TW200901961A (enExample) |
| WO (1) | WO2008103310A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI444187B (zh) | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
| CA2640090A1 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| JP2009524683A (ja) | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のためのビニル−フェニル誘導体 |
| JP2009528273A (ja) | 2006-01-25 | 2009-08-06 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用の置換ビアリール化合物 |
| CA2645434A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceutical Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| PL2563776T3 (pl) | 2010-04-27 | 2017-01-31 | Calcimedica Inc | Związki, które modulują wewnątrzkomórkowy wapń |
| WO2012027710A2 (en) | 2010-08-27 | 2012-03-01 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| ES2748022T3 (es) | 2011-11-21 | 2020-03-12 | Univ Tsukuba | Modulador de la actividad, medicamento que comprende el mismo, uso de ratón deficiente del gen de CD300a y anticuerpo antiCD300a |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2918289A4 (en) * | 2012-11-07 | 2016-06-15 | Univ Tsukuba | MEDICAMENT WITH MODULATOR OF THE ACTIVITY OF A CD300A EXPRESSIVE CELL RELATED TO ALLERGIC DISEASES, CD300A GENE KNOCKOUT MOUSE, AND USE OF A MODULATOR OF THE ACTIVITY OF A CD300A EXPRESSIVE CELL |
| EA036265B1 (ru) | 2015-02-27 | 2020-10-20 | Кальцимедика, Инк. | Лечение панкреатита |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| US20230242640A1 (en) * | 2018-08-22 | 2023-08-03 | Ose Immunotherapeutics | ANTI-SIRPg Compounds |
| MX2021003094A (es) | 2018-09-14 | 2021-05-12 | Rhizen Pharmaceuticals A G | Composiciones que comprenden un inhibidor de crac y un corticosteroide y métodos de uso de estas. |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1793518A1 (de) * | 1964-10-02 | 1972-02-03 | Searle & Co | Verfahren zur Herstellung von 1-Vinyltetralolen |
| WO1988008836A2 (en) | 1987-05-15 | 1988-11-17 | Schering Corporation | Aryl substituted naphthalene, benzoxepine, benzazepine, benzocycloheptene derivatives |
| CA2258313A1 (en) * | 1996-06-21 | 1997-12-24 | Allergan Sales, Inc. | Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
| DE19805370A1 (de) * | 1997-03-14 | 1998-09-17 | Gruenenthal Gmbh | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
| DE19833786A1 (de) * | 1998-07-18 | 2000-01-20 | Schering Ag | Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| CA2345459A1 (en) * | 1998-11-12 | 2000-05-18 | Regine Bohacek | Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| ES2220140T3 (es) | 1998-12-22 | 2004-12-01 | Tanabe Seiyaku Co., Ltd. | Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1). |
| EP1330448A2 (en) * | 2000-06-20 | 2003-07-30 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| AU2003235097A1 (en) * | 2002-04-24 | 2003-11-10 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
| JP2004002402A (ja) * | 2002-04-24 | 2004-01-08 | Takeda Chem Ind Ltd | Ｃｃｒ拮抗作用を有する化合物の用途 |
| JP2004196702A (ja) * | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| ES2222833B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos. |
| DE102004044680B3 (de) * | 2004-09-09 | 2006-06-08 | Schering Ag | Alkyliden-Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate |
| WO2006065842A2 (en) * | 2004-12-13 | 2006-06-22 | Synta Pharmaceuticals Corp. | 5,6,7,8-tetrahydroquinolines and related compounds and uses thereof |
| US7863270B2 (en) * | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
-
2008
- 2008-02-15 WO PCT/US2008/002077 patent/WO2008103310A1/en not_active Ceased
- 2008-02-15 CA CA002678615A patent/CA2678615A1/en not_active Abandoned
- 2008-02-15 AU AU2008219115A patent/AU2008219115A1/en not_active Abandoned
- 2008-02-15 EP EP08725685A patent/EP2129219A4/en not_active Withdrawn
- 2008-02-15 JP JP2009549637A patent/JP2010519206A/ja active Pending
- 2008-02-15 TW TW097105319A patent/TW200901961A/zh unknown
-
2009
- 2009-08-14 US US12/541,623 patent/US8809396B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010519206A5 (enExample) | ||
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2010509342A5 (enExample) | ||
| JP2010535218A5 (enExample) | ||
| JP2021532124A (ja) | Ｎｌｒｐ３インフラマソーム阻害剤 | |
| CA2800834C (en) | Pyrazolo [1,5-a] pyrimidines as antiviral agents | |
| JP2020537657A5 (enExample) | ||
| JP2019163290A5 (enExample) | ||
| RU2328499C2 (ru) | Производные пирролопиридазина, фармацевтическая композиция, способ профилактики или лечения заболеваний, применение в качестве ингибитора фосфодиэстеразы iv, и/или продуцирования tnf | |
| JP2020528889A5 (enExample) | ||
| JP2017501234A5 (enExample) | ||
| JP6387361B2 (ja) | ピリジン−４−イル誘導体 | |
| JP2017505808A5 (enExample) | ||
| WO2007116866A1 (ja) | ヘテロ化合物 | |
| JPH0346474B2 (enExample) | ||
| CN108727378A (zh) | 新型异喹啉类化合物及其医药用途 | |
| HRP20171610T1 (hr) | Selektivni inhibitori pi3k delta | |
| TWI831325B (zh) | 作為atr抑制劑的萘啶衍生物及其製備方法 | |
| JP4669839B2 (ja) | ジフェニルピリジン誘導体、その製造法および治療用途 | |
| JP2012528105A5 (enExample) | ||
| JP2019514956A (ja) | 置換イミダゾ［１，２−ｂ］ピリダジン、置換イミダゾ［１，５−ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 | |
| CZ298850B6 (cs) | Zpusob výroby diarylpyridinových derivátu | |
| CA3068128A1 (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| JP2018502083A5 (enExample) | ||
| JP6513075B2 (ja) | オートタキシン阻害活性を有する縮合ピラゾール誘導体 |